Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elinzanetant - Bayer

Next Previous
Drug Profile

Elinzanetant - Bayer

Alternative Names: BAY-3427080; GSK 1144814A; GSK-1144814; Lynkuet; NT 814

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Bayer; GlaxoSmithKline; NeRRe Therapeutics
  • Class 2 ring heterocyclic compounds; Alcohols; Amides; Antipsychotics; Drug withdrawal therapies; Fluorinated hydrocarbons; Fluorobenzenes; Oxazines; Piperazines; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Vasomotor symptoms
  • Phase II Sleep disorders
  • Discontinued Opioid-related disorders; Schizophrenia

Most Recent Events

  • 14 Jan 2026 Bayer completes a phase I bioavailability trial in Vasomotor-symptoms (In volunteers) in Canada (PO) (NCT07229404)
  • 17 Nov 2025 Launched for Vasomotor symptoms in USA (PO) before November 2025 (Martindale, March 2026)
  • 17 Nov 2025 Registered for Vasomotor symptoms in Norway, Iceland, Liechtenstein, European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top